HRP20090012T3 - 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof - Google Patents

2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof

Info

Publication number
HRP20090012T3
HRP20090012T3 HR20090012T HRP20090012T HRP20090012T3 HR P20090012 T3 HRP20090012 T3 HR P20090012T3 HR 20090012 T HR20090012 T HR 20090012T HR P20090012 T HRP20090012 T HR P20090012T HR P20090012 T3 HRP20090012 T3 HR P20090012T3
Authority
HR
Croatia
Prior art keywords
group
alkyl
aryl
fluoroalkyl
atom
Prior art date
Application number
HR20090012T
Other languages
English (en)
Croatian (hr)
Inventor
Dubois Laurent
Evanno Yannick
Maloizel Christian
Sevrin Mireille
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of HRP20090012T3 publication Critical patent/HRP20090012T3/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
HR20090012T 2004-05-11 2005-05-10 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof HRP20090012T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0405055A FR2870239B1 (fr) 2004-05-11 2004-05-11 Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
PCT/FR2005/001154 WO2005121099A1 (fr) 2004-05-11 2005-05-10 Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
HRP20090012T3 true HRP20090012T3 (en) 2009-02-28

Family

ID=34947852

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090012T HRP20090012T3 (en) 2004-05-11 2005-05-10 2h or 3h-benzo[e]indazol-1-yle carbamate derivatives, the preparation and therapeutic use thereof

Country Status (32)

Country Link
US (3) US7501449B2 (pt)
EP (1) EP1747201B8 (pt)
JP (1) JP4909889B2 (pt)
KR (1) KR101165483B1 (pt)
CN (1) CN100577648C (pt)
AR (1) AR049090A1 (pt)
AT (1) ATE411295T1 (pt)
AU (1) AU2005251982B2 (pt)
BR (1) BRPI0508563A (pt)
CA (1) CA2557942C (pt)
CR (1) CR8570A (pt)
CY (1) CY1108710T1 (pt)
DE (1) DE602005010418D1 (pt)
DK (1) DK1747201T3 (pt)
EC (1) ECSP066810A (pt)
ES (1) ES2315898T3 (pt)
FR (1) FR2870239B1 (pt)
HR (1) HRP20090012T3 (pt)
IL (1) IL177632A (pt)
MA (1) MA28372A1 (pt)
NO (1) NO20064073L (pt)
NZ (1) NZ549330A (pt)
PL (1) PL1747201T3 (pt)
PT (1) PT1747201E (pt)
RS (1) RS50724B (pt)
RU (1) RU2379293C2 (pt)
SI (1) SI1747201T1 (pt)
TN (1) TNSN06258A1 (pt)
TW (1) TWI349004B (pt)
UA (1) UA85866C2 (pt)
WO (1) WO2005121099A1 (pt)
ZA (1) ZA200607244B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2870239B1 (fr) 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.
WO2007088528A1 (en) * 2006-02-03 2007-08-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Microtubule targeting agents
CL2008000793A1 (es) * 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
ES2651367T3 (es) * 2013-07-15 2018-01-25 Basf Se Compuestos plaguicidas

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607076A1 (fr) * 1993-01-15 1994-07-20 Synthelabo Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
FR2741073B1 (fr) * 1995-11-09 1997-12-12 Synthelabo Derives de 4,5-dihydroimidazo(1,2-a)pyrrolo(1,2,3-cd) benzimidazole, leur preparation et leur application en therapeutique
AR006520A1 (es) * 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
JP2004508359A (ja) * 2000-09-06 2004-03-18 ニューロゲン　コーポレイション アリール置換テトラヒドロインダゾール、及び、ｇａｂａ−ａ受容体に対するリガンドとしてのそれらの使用
KR100770327B1 (ko) * 2000-09-18 2007-10-25 에자이 알앤드디 매니지먼트 가부시키가이샤 피리다지논 및 트리아지논 화합물류 및 그들의 의약 용도
FR2870239B1 (fr) * 2004-05-11 2006-06-16 Sanofi Synthelabo Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique.

Also Published As

Publication number Publication date
KR20070007796A (ko) 2007-01-16
IL177632A (en) 2012-07-31
AU2005251982A1 (en) 2005-12-22
US7501449B2 (en) 2009-03-10
CA2557942A1 (fr) 2005-12-22
ATE411295T1 (de) 2008-10-15
JP2007537212A (ja) 2007-12-20
UA85866C2 (uk) 2009-03-10
NZ549330A (en) 2010-08-27
TW200604181A (en) 2006-02-01
CN100577648C (zh) 2010-01-06
CN1930131A (zh) 2007-03-14
RU2006132325A (ru) 2008-03-20
US20120108584A1 (en) 2012-05-03
JP4909889B2 (ja) 2012-04-04
EP1747201A1 (fr) 2007-01-31
RU2379293C2 (ru) 2010-01-20
NO20064073L (no) 2006-11-06
FR2870239B1 (fr) 2006-06-16
WO2005121099A1 (fr) 2005-12-22
ES2315898T3 (es) 2009-04-01
CA2557942C (fr) 2013-08-06
AR049090A1 (es) 2006-06-28
FR2870239A1 (fr) 2005-11-18
CR8570A (es) 2007-10-04
MA28372A1 (fr) 2006-12-01
IL177632A0 (en) 2006-12-31
CY1108710T1 (el) 2014-04-09
BRPI0508563A (pt) 2007-08-14
TWI349004B (en) 2011-09-21
US20070105932A1 (en) 2007-05-10
DE602005010418D1 (de) 2008-11-27
SI1747201T1 (sl) 2009-04-30
AU2005251982B2 (en) 2011-04-28
PL1747201T3 (pl) 2009-04-30
US20090143380A1 (en) 2009-06-04
EP1747201B1 (fr) 2008-10-15
HK1104288A1 (en) 2008-01-11
TNSN06258A1 (fr) 2007-12-03
US8114899B2 (en) 2012-02-14
PT1747201E (pt) 2009-01-19
EP1747201B8 (fr) 2009-02-18
DK1747201T3 (da) 2009-02-16
RS50724B (sr) 2010-08-31
US8258168B2 (en) 2012-09-04
KR101165483B1 (ko) 2012-07-13
ZA200607244B (en) 2008-04-30
ECSP066810A (es) 2006-11-16

Similar Documents

Publication Publication Date Title
ATE556058T1 (de) 1-(2h)-isochinolonderivat
NO20090952L (no) N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
NO20082346L (no) Hydrazonderivater og anvendelser derav
CY1118723T1 (el) Ενωσεις βενζοθειαζολιου και αζαβενζοθειαζολιου χρησιμες ως αναστολεiς κινασης
NO20076006L (no) Acetylenderivater
EA200800873A1 (ru) Конденсированные гетероциклические соединения, полезные в качестве модуляторов киназы
BRPI0506817A (pt) inibidores seletivos de quinase
DE60225671D1 (de) Pharmazeutisch wirksame piperidinderivate
ATE478044T1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
NO20091892L (no) Krystallinsk form av (3S)-3-(N-(N`-(2-tert-butylfenyl)oksamyl) alaninyl)amino-5-(2`,3`,5`,6`-tetrafluorfenoksy)-4 oksopentanoisk syre
MEP8409A (en) Fused heterocyclic compound
NO20062185L (no) Hepatitt C virus-inhibitorer
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
CY1106881T1 (el) (3-οξο-3,4-διυδρο-κινοξαλιν-2-υλο-αμινο) - βενζαμιδικα παραγωγα και σχετικες ενωσεις ως αναστολεις της φωσφορυλασης γλυκογονου για την αντιμετωπιση του διαβητη και της παχυσαρκιας.
NO20064326L (no) Aryl- og heteroarylpiperidinkarboksylatderivater, deres fremstilling og anvendelse derav i form av FAAH enzyminhibitorer
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
TNSN07469A1 (en) N-(heteroaryl) -1- heteroarylalkyl -1h-indole-2- carboxamide derivatives, preparation and use thereof
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
TW200635896A (en) N-(heteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic application thereof